GC Wealth Management RIA LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

GC Wealth Management RIA LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 510.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 2,297 shares of the biopharmaceutical company’s stock after buying an additional 1,921 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Regeneron Pharmaceuticals were worth $1,775,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in REGN. Vanguard Group Inc. boosted its stake in Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after buying an additional 26,884 shares during the last quarter. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 1.0% during the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after acquiring an additional 45,513 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the last quarter. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $656.01 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The firm has a market capitalization of $69.35 billion, a P/E ratio of 15.98, a P/E/G ratio of 1.45 and a beta of 0.24. The business’s 50-day simple moving average is $635.78 and its 200-day simple moving average is $714.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on REGN shares. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Barclays cut their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the company a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.